What's Happening With Moderna Stock?

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

Moderna, Merck's skin cancer vaccine shows sustained benefit in long-term follow-up

Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, when used ...